Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. / On behalf of the ABIRISK Consortium.

I: Journal of Neuroimmunology, Bind 326, 01.2019, s. 19-27.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

On behalf of the ABIRISK Consortium 2019, 'Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study', Journal of Neuroimmunology, bind 326, s. 19-27. https://doi.org/10.1016/j.jneuroim.2018.11.002

APA

On behalf of the ABIRISK Consortium (2019). Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 326, 19-27. https://doi.org/10.1016/j.jneuroim.2018.11.002

Vancouver

On behalf of the ABIRISK Consortium. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology. 2019 jan.;326:19-27. https://doi.org/10.1016/j.jneuroim.2018.11.002

Author

On behalf of the ABIRISK Consortium. / Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. I: Journal of Neuroimmunology. 2019 ; Bind 326. s. 19-27.

Bibtex

@article{f7f7a2605ec84157aac231073c8405ee,
title = "Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study",
abstract = "Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.",
keywords = "Anti-drug antibodies, Bridging ELISA, Interferon-beta, Luciferase-based bioassay, Multiple sclerosis, Neutralizing antibodies",
author = "Jensen, {Poul Erik H.} and Clemens Warnke and Kathleen Ingenhoven and Luca Piccoli and Marcia Gasis and Christina Hermanrud and Fernandez-Rodriguez, {Blanca M.} and Malin Ryner and Daniel Kramer and Jenny Link and Ryan Ramanujam and Michael Auer and Dorothea Buck and Verena Grummel and Elisa Bertotti and Nicolas Fissolo and Bego{\~n}a Oliver-Martos and Petra Nytrova and Michael Khalil and Michael Guger and Sandra Rathmaier and Claudia Sievers-Stober and Lindberg, {Raija L.P.} and Signe H{\"a}ssler and Delphine Bachelet and Orhan Aktas and Naoimh Donnellan and Andy Lawton and Bernhard Hemmer and Havrdova, {Eva Kubala} and Bernd Kieseier and Hartung, {Hans Peter} and Manuel Comabella and Xavier Montalban and Tobias Derfuss and Finn Sellebjerg and Pierre D{\"o}nnes and Marc Pallardy and Sebastian Spindeldreher and Philippe Bro{\"e}t and Florian Deisenhammer and Anna Fogdell-Hahn and Sorensen, {Per Soelberg} and {On behalf of the ABIRISK Consortium}",
year = "2019",
month = jan,
doi = "10.1016/j.jneuroim.2018.11.002",
language = "English",
volume = "326",
pages = "19--27",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

AU - Jensen, Poul Erik H.

AU - Warnke, Clemens

AU - Ingenhoven, Kathleen

AU - Piccoli, Luca

AU - Gasis, Marcia

AU - Hermanrud, Christina

AU - Fernandez-Rodriguez, Blanca M.

AU - Ryner, Malin

AU - Kramer, Daniel

AU - Link, Jenny

AU - Ramanujam, Ryan

AU - Auer, Michael

AU - Buck, Dorothea

AU - Grummel, Verena

AU - Bertotti, Elisa

AU - Fissolo, Nicolas

AU - Oliver-Martos, Begoña

AU - Nytrova, Petra

AU - Khalil, Michael

AU - Guger, Michael

AU - Rathmaier, Sandra

AU - Sievers-Stober, Claudia

AU - Lindberg, Raija L.P.

AU - Hässler, Signe

AU - Bachelet, Delphine

AU - Aktas, Orhan

AU - Donnellan, Naoimh

AU - Lawton, Andy

AU - Hemmer, Bernhard

AU - Havrdova, Eva Kubala

AU - Kieseier, Bernd

AU - Hartung, Hans Peter

AU - Comabella, Manuel

AU - Montalban, Xavier

AU - Derfuss, Tobias

AU - Sellebjerg, Finn

AU - Dönnes, Pierre

AU - Pallardy, Marc

AU - Spindeldreher, Sebastian

AU - Broët, Philippe

AU - Deisenhammer, Florian

AU - Fogdell-Hahn, Anna

AU - Sorensen, Per Soelberg

AU - On behalf of the ABIRISK Consortium

PY - 2019/1

Y1 - 2019/1

N2 - Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

AB - Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

KW - Anti-drug antibodies

KW - Bridging ELISA

KW - Interferon-beta

KW - Luciferase-based bioassay

KW - Multiple sclerosis

KW - Neutralizing antibodies

U2 - 10.1016/j.jneuroim.2018.11.002

DO - 10.1016/j.jneuroim.2018.11.002

M3 - Journal article

C2 - 30447419

AN - SCOPUS:85056449193

VL - 326

SP - 19

EP - 27

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -

ID: 241938547